JP2009510093A5 - - Google Patents

Download PDF

Info

Publication number
JP2009510093A5
JP2009510093A5 JP2008533624A JP2008533624A JP2009510093A5 JP 2009510093 A5 JP2009510093 A5 JP 2009510093A5 JP 2008533624 A JP2008533624 A JP 2008533624A JP 2008533624 A JP2008533624 A JP 2008533624A JP 2009510093 A5 JP2009510093 A5 JP 2009510093A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
disease
isolated
soluble polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008533624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009510093A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/037950 external-priority patent/WO2007038703A2/en
Publication of JP2009510093A publication Critical patent/JP2009510093A/ja
Publication of JP2009510093A5 publication Critical patent/JP2009510093A5/ja
Pending legal-status Critical Current

Links

JP2008533624A 2005-09-28 2006-09-28 Il−17aおよびil−17fアンタゴニストならびにその使用方法 Pending JP2009510093A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72116205P 2005-09-28 2005-09-28
US75379405P 2005-12-22 2005-12-22
US77202206P 2006-02-10 2006-02-10
US78224706P 2006-03-14 2006-03-14
PCT/US2006/037950 WO2007038703A2 (en) 2005-09-28 2006-09-28 Il-17a and il-17f antagonists and methods of using the same

Publications (2)

Publication Number Publication Date
JP2009510093A JP2009510093A (ja) 2009-03-12
JP2009510093A5 true JP2009510093A5 (enExample) 2009-11-12

Family

ID=37672342

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008533624A Pending JP2009510093A (ja) 2005-09-28 2006-09-28 Il−17aおよびil−17fアンタゴニストならびにその使用方法

Country Status (16)

Country Link
US (1) US20070238658A1 (enExample)
EP (1) EP1931697B1 (enExample)
JP (1) JP2009510093A (enExample)
KR (1) KR20080056241A (enExample)
AT (1) ATE481424T1 (enExample)
AU (1) AU2006294511B2 (enExample)
BR (1) BRPI0616589A2 (enExample)
CA (1) CA2621623A1 (enExample)
CY (1) CY1110856T1 (enExample)
DE (1) DE602006016965D1 (enExample)
DK (1) DK1931697T3 (enExample)
EA (1) EA015351B1 (enExample)
IL (1) IL189726A0 (enExample)
PL (1) PL1931697T3 (enExample)
PT (1) PT1931697E (enExample)
WO (1) WO2007038703A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1641822T3 (da) 2003-07-08 2013-07-22 Genentech Inc Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf.
EP1765865A2 (en) * 2004-06-10 2007-03-28 ZymoGenetics, Inc. Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ActRII受容体ポリペプチド、方法、および組成物
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP2500360B1 (en) 2005-10-31 2015-08-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
BRPI0618947B1 (pt) 2005-11-23 2022-07-19 Acceleron Pharma Inc Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea
JP2009520479A (ja) * 2005-12-22 2009-05-28 ラボラトワール セローノ ソシエテ アノニム 溶解性il−17rc変異体及びそれらの使用
WO2008039553A1 (en) * 2006-02-10 2008-04-03 Zymogenetics, Inc. Soluble il-17rcx4 and methods of using in inflammation
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
TWI584815B (zh) 2007-02-01 2017-06-01 艾瑟勒朗法瑪公司 活化素-ActRIIa拮抗劑及其治療或預防乳癌之用途
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
MX2009008510A (es) 2007-02-09 2010-01-15 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer.
CA2679588A1 (en) 2007-03-26 2008-10-02 Zymogenetics, Inc. Soluble il-17ra/rc fusion proteins and related methods
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
US8460647B2 (en) 2007-04-20 2013-06-11 Amgen Inc. Pre-ligand assembly domain of the IL-17 receptor
BRPI0813262A2 (pt) * 2007-06-20 2015-04-14 Schering Corp Biomarcadores de destruição de articulação para terapia de doença inflamatória de articulação anti-il-17a
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
DK3750552T5 (da) 2008-08-14 2024-08-26 Acceleron Pharma Inc Gdf-fælder
EP2331136B1 (en) 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
AU2010204985A1 (en) 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
CN102548617B (zh) * 2009-03-30 2017-11-07 阿塞勒隆制药公司 Bmp‑alk3拮抗剂和促进骨生长的用途
MX355042B (es) 2009-06-08 2018-04-02 Acceleon Pharma Inc Metodos para aumentar adipositos termogenicos.
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
CA2772162C (en) 2009-08-27 2018-05-22 Covagen Ag Anti-il-17a fynomers and medical uses thereof
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt拮抗劑及治療和篩選方法
CN102971337B (zh) 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
CA2817008A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma Inc. Actriia binding agents and uses thereof
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
JP2015536933A (ja) 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Wnt経路結合剤を用いて神経内分泌腫瘍を処置する方法
RU2678117C2 (ru) 2012-11-02 2019-01-23 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN103992400B (zh) * 2014-05-29 2017-01-04 江苏吴中医药集团有限公司苏州中凯生物制药厂 重组人血管内皮抑素的复性液及其制备、使用方法
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP3227675B1 (en) 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
KR20210049814A (ko) * 2018-08-29 2021-05-06 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 fc 융합 단백질 투약 요법
CN113789346A (zh) * 2021-08-25 2021-12-14 北京伟德杰生物科技有限公司 长效化重组人白细胞介素2融合蛋白及其制备方法和应用
WO2025226984A1 (en) * 2024-04-24 2025-10-30 Mopac Biologics, Inc. Human il-17 binding polypeptides

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
WO1997017451A2 (en) 1995-11-09 1997-05-15 Zymogenetics, Inc. Production of gad65 in methylotrophic yeast
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
IL128073A0 (en) 1996-07-17 1999-11-30 Zymogenetics Inc Transformation of pichia methanolica
JP2002514049A (ja) 1996-07-17 2002-05-14 ザイモジェネティクス,インコーポレイティド ピヒア・メタノリカの栄養要求性突然変異体の製造
US6569645B2 (en) * 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6579520B2 (en) * 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
US20050147609A1 (en) * 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
ES2292242T5 (es) * 1998-05-15 2011-05-04 Genentech, Inc. Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
DE60034564T2 (de) 1999-07-07 2007-12-27 Zymogenetics, Inc., Seattle Menschlicher cytokinrezeptor
US20030199041A1 (en) * 1999-07-07 2003-10-23 Presnell Scott R. Interleukin-17 receptor homologue
US20030092881A1 (en) * 2000-05-24 2003-05-15 Gorman Daniel M. Mammalian receptor proteins; related reagents and methods
US20040197306A1 (en) * 2000-05-24 2004-10-07 Gorman Daniel M. Mammalian receptor proteins; related reagents and methods
CA2425506A1 (en) * 2000-10-18 2002-08-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
US20040097447A1 (en) * 2002-11-16 2004-05-20 Isis Pharmaceuticals Inc. Modulation of interleukin 22 receptor expression
WO2004019866A2 (en) * 2002-08-28 2004-03-11 Immunex Corporation Compositions and methods for treating cardiovascular disease
DK1641822T3 (da) 2003-07-08 2013-07-22 Genentech Inc Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf.
EP1765865A2 (en) 2004-06-10 2007-03-28 ZymoGenetics, Inc. Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation

Similar Documents

Publication Publication Date Title
JP2009526084A5 (enExample)
JP2009148257A5 (enExample)
JP2010273685A5 (enExample)
JP2010522564A5 (enExample)
JP2008509227A5 (enExample)
JP2009527226A5 (enExample)
JP2010511056A5 (enExample)
JP2016510736A5 (enExample)
JP2010220614A5 (enExample)
JP2014521313A5 (enExample)
CN114957472B (zh) 抗IL-4Rα的单域抗体以及应用和药物
JP2007530435A5 (enExample)
FI3842456T3 (fi) Monoklonaalinen interleukiini-31-vasta-aine
JP2009542219A5 (enExample)
JP2006516189A5 (enExample)
JP2009539349A5 (enExample)
JP2003527078A5 (enExample)
EP3483283A1 (en) Method for screening agents for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, tnf, g-csf, cxcl1, cxcl2, or cxcl5 and agent for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, tnf, g-csf, cxcl1, cxcl2, or cxcl5
JP2007075118A5 (enExample)
CN110003329B (zh) 多肽、il17a/f单域抗体、核苷酸序列及试剂盒
CN102625836B (zh) Hmgb1结合核酸分子及其用途
JP2024516962A5 (enExample)
JP2013531967A5 (enExample)
JPWO2023282161A5 (enExample)
JP2008532931A5 (enExample)